Healthcare / BiotechnologyHelsinki
$0.52
-0.01 (-1.87%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-22.5M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$111M
P/E
N/A
•EV/EBITDA
N/A
•ROE
147.3%
↑Gross Margin
N/A
•Debt/Equity
-1.33
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-27.3M · FCF $-18.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-27.3M | $-27.3M | $-25.9M | $-30.9M | $-28.7M |
| EBITDA | $-25.7M | $-25.7M | $-21.7M | $-28.5M | $-27.1M |
| EPS | — | — | -0.27 | -0.37 | -0.40 |
| Balance Sheet | |||||
| Debt/Equity | -1.33 | -1.33 | -1.24 | -0.86 | -1.16 |
| Current Ratio | 0.84 | 0.84 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-18.1M | $-18.1M | $-22.5M | $-23.9M | $-23.4M |
| Returns | |||||
| ROE | 147.3% | 147.3% | 265.5% | 204.1% | 250.3% |
| Growth & Yield | |||||
| EPS Growth | — | — | 27.3% | 7.7% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-82.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.27 → n/d
Residual
-82.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.